Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010

Background/purpose Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Graefe's archive for clinical and experimental ophthalmology Ročník 251; číslo 11; s. 2499 - 2503
Hlavní autori:	Cohen, Salomon Y., Dubois, Lise, Ayrault, Sandrine, Dourmad, Pauline, Delahaye-Mazza, Corinne, Fajnkuchen, Franck, Nghiem-Buffet, Sylvia, Quentel, Gabriel, Tadayoni, Ramin
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2013 Springer Nature B.V
Predmet:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Exudates and Transudates Female Fluorescein Angiography Humans Intravitreal Injections Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab Retinal Disorders Retrospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology Exudative age-related macular degeneration Real-life retrospective study Ranibizumab
ISSN:	0721-832X, 1435-702X, 1435-702X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!